Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.70 |
| ▸ | MAPT | P10636 | 11/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.70 |
| ▸ | MEN1 | O00255 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 3/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17466932 | 0.83 | MAPT (1.00) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL6201800 | 0.78 | KDM4E (0.53) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL18805084 | 0.78 | KDM4E (0.53) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL6201799 | 0.78 | KDM4E (0.53) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL26552220 | 0.78 | KDM4E (0.53) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20824922 | 0.78 | KMT2A (0.80) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL30844141 | 0.77 | ESR1 (0.63) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL60843 | 0.76 | MAPT (0.76) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL17466936 | 0.76 | MAPT (0.85) | KMT2AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL22208284 | 0.75 | KMT2A (1.00) | KMT2AMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461701-B | Calixarene-derivatized supramolecular macrocyclic host compound, preparation method and application thereof | 上海大学 | 2022-10-11 | — | — | CN | claimed |
| CN-113717076-B | Preparation method for obtaining methane functional product based on iron/light combined catalysis | 大连理工大学 | 2022-08-02 | — | — | CN | claimed |
| CN-113461701-A | Calixarene-derivatized supramolecular macrocyclic host compound, preparation method and application thereof | 上海大学 | 2021-10-01 | — | — | CN | claimed |
| CN-113461701-B | Calixarene-derivatized supramolecular macrocyclic host compound, preparation method and application thereof | 上海大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-113717076-B | Preparation method for obtaining methane functional product based on iron/light combined catalysis | 大连理工大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | DREXEL UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
| US-20210376381-A1 | ADDITIVES FOR ELECTROLYTES IN Li-IONS BATTERIES | HYDRO-QUéBEC (CA) | 2021-12-02 | — | — | US | disclosed |
| CN-113717076-A | Preparation method for obtaining methane functional product based on iron/light combined catalysis | 大连理工大学 | 2021-11-30 | — | — | CN | disclosed |
| CN-113461701-A | Calixarene-derivatized supramolecular macrocyclic host compound, preparation method and application thereof | 上海大学 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020069619-A1 | ADDITIVES FOR ELECTROLYTES IN LI-ION BATTERIES | HYDRO-QUéBEC (CA) | 2020-04-09 | — | — | WO | disclosed |
| US-6355653-B1 | DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS | HOFFMANN-LA ROCHE INC. | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | SQOR, QSOX1, KEAP1 | KMT2A 677/4885MAPT 4525/4885KDM4E 316/4885 |
| US-20210376381-A1 | ADDITIVES FOR ELECTROLYTES IN Li-IONS BATTERIES | NDUFB9, SLC26A4, SLC9B2 | KMT2A 3868/4885MAPT 2848/4885KDM4E 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.